Shares of Vertex Pharmaceuticals Incorporated VRTX were down 11.4% yesterday after the company announced data from a phase II ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with ...